contract_awardAwarded Friday, July 10, 2026Analyzed

LEIDOS BIOMEDICAL RESEARCH INC: $338M Department of Health and Human Services Contract

Bullish

Summary

Leidos Holdings ($LDOS) received a $338M delivery order from the NIH National Cancer Institute for operational support in FY26-FY27. This award represents ~2.2% of Leidos' annual revenue and reinforces its role in federal health research services.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.Leidos wins $338M NIH contract for NCI operations, adding to backlog.
  • 2.Contract is ~2.2% of Leidos' annual revenue, a meaningful but not transformative boost.
  • 3.Reinforces Leidos' position in federal health services, a stable growth area.

Market Implications

For $LDOS, this contract adds to a growing backlog in health services, supporting revenue visibility. The stock may see a slight positive drift as the market prices in the award, but given Leidos' size, the impact is modest. No other publicly traded companies are directly affected.

Full Analysis

  1. Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings ($LDOS), was awarded a $338M delivery order by the National Institutes of Health's National Cancer Institute. The contract covers operational task orders for FY26-FY27, supporting NCI's mission. 2) Leidos Holdings, a $15.3B revenue company, will see this $338M contract contribute to its Health segment, which provides scientific, technical, and operational services to federal health agencies. This is a meaningful but not transformative addition, representing ~2.2% of annual revenue. 3) While no specific bill directly authorizes this contract, the broader NIH budget is supported by annual appropriations bills. Related bills like HR9672 (Vaccine Injury Compensation) and HR9675 (opioid grants) signal continued healthcare spending, but this contract is a routine operational award. 4) Key subcontractors may include small-cap IT and lab services firms, but specific names are not disclosed. Leidos often partners with specialized research organizations. 5) Historically, Leidos has maintained a strong relationship with NIH, and such task orders provide predictable revenue streams. The stock tends to react modestly to contract wins of this size, with sustained performance tied to overall federal health spending.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$LDOS▲ Bullish
Est. $338.0M$338.0M revenue impact

What the bill does

Direct contract award to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, for operational support at the National Cancer Institute.

Who must act

Department of Health and Human Services / National Institutes of Health awarding to Leidos Biomedical Research Inc.

What happens

$338M added to Leidos' backlog, representing approximately 2.2% of FY2025 revenue ($15.3B).

Stock impact

Leidos' Health segment, which includes biomedical research services, will see a meaningful boost. This contract reinforces Leidos' position as a key NIH contractor, supporting stable revenue growth in a high-margin services area.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderAug 26, 2026

Declaring a National Emergency to Secure the United States Bulk-Power System

This executive order declares a national emergency to restrict foreign-produced bulk-power system electric equipment that poses national security risks, prohibiting new transactions involving equipment from covered foreign entities and allowing the Secretary of Energy to impose conditions on existing equipment. It directs the Secretary of Energy, in coordination with multiple agencies, to identify, mitigate, and potentially replace risky equipment, and establishes a pre-qualification list for approved vendors.

presidential_memorandumAug 20, 2026

The National Space Transportation Policy

This memorandum directs multiple agencies to expand and modernize U.S. space launch and reentry infrastructure to support over 1,000 launches annually by 2030, expedite permitting and environmental reviews, develop new federal reentry sites, and strengthen the space transportation industrial base. It mandates range scheduling transparency, spectrum reliability, and workforce development, with specific reports and plans due within 90 to 240 days.

proclamationAug 13, 2026

Adjusting Imports of Unmanned Aircraft Systems and Unmanned Aircraft Systems Components into the United States

This proclamation imposes a 100% ad valorem tariff on imports of unmanned aircraft systems (UAS) over 25 kg, those with thermal imagers, docking stations, and certain components, and a 25% tariff on UAS under 25 kg and other components, citing national security under Section 232 of the Trade Expansion Act. It also authorizes the Department of Commerce to establish an onshoring program offering preferential tariff treatment for companies that build new U.S. manufacturing facilities for UAS and components.

Contract Details

Recipient

LEIDOS BIOMEDICAL RESEARCH INC

Award Amount

$337,911,652

Awarding Agency

Department of Health and Human Services

Sub-Agency

National Institutes of Health

Contract Type

DELIVERY ORDER

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →